弥漫大B细胞淋巴瘤
| 弥漫大B细胞淋巴瘤 | |
|---|---|
| 类型 | B細胞淋巴瘤、aggressive B-cell non-Hodgkin lymphoma[*] |
| 分类和外部资源 | |
| 醫學專科 | 肿瘤学 |
| ICD-11 | 2A81 |
| ICD-O | M9680/3 |
| eMedicine | 202969 |
| MeSH | D016403 |
| Orphanet | 544 |
弥漫大B细胞淋巴瘤（Diffuse large B-cell lymphoma DLBL or DLBCL）是一种常见的恶性淋巴瘤。占成人淋巴瘤患者近40%。[1]
分型
根据其基因活性，DLBL可分为2种[2]或3种[3]主要亚型:
- 活化B细胞淋巴瘤（ABC-DLBCL）
- 生发中心B细胞淋巴瘤（GCB-DLBCL）
- 原发纵隔大B细胞淋巴瘤（PMBL）
治疗
标准化疗方案为CHOP方案。改良的CHOP-R方案可以改善生存率[4]，尤其是对于老年人。[2]
预后
生发中心亚型的预后最好，5年生存率达60%。[2]
参考文献
- ^ Pathobiology of the aggressive and highly aggressive non-Hodgkin's lymphomas[永久失效連結]
- ^ 2.0 2.1 2.2 Turgeon, Mary Louise. Clinical hematology: theory and procedures. Hagerstown, MD: Lippincott Williams & Wilkins. 2005: 285–286. ISBN 0-7817-5007-5.
- ^ Lenz G, Wright GW, Emre NC; et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. U.S.A. September 2008, 105 (36): 13520–5. PMID 18765795. doi:10.1073/pnas.0804295105.
- ^ Sehn LH, Berry B, Chhanabhai M; et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. March 2007, 109 (5): 1857–61. PMID 17105812. doi:10.1182/blood-2006-08-038257.[永久失效連結]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||